Pharmacology Books

Book SynopsisTrade ReviewFrom customer reviews of the previous edition: 2018 BMA Awards: Winner, Internal Medicine "This book is amazing helpful. It goes through every core condition you need and is simply written and to the point but has all the information that is needed. As a medical student this book has been great for my studies" "Great book, small enough to take on the wards, full of information on the go. I love it." "Excellent little companion book." "Good book. It has all the basics that student needs to revise, write assignments etc"Table of Contents1 Ethics and Communication 2 Infectious Diseases 3 Gastroenterology and Nutrition 4 Liver, Biliary Tract, and Pancreatic Disease 5 Haematological Disease 6 Malignant Disease 7 Rheumatology 8 Water, Electrolytes, and Acid-Base Balance 9 Renal Disease 10 Cardiovascular Disease 11 Respiratory Disease 12 Critical Care Medicine 13 Clinical Pharmacology and Toxicology 14 Endocrine Disease 15 Diabetes Mellitus and Other Disorders of Metabolism 16 The Special Senses 17 Neurology 18 Dermatology 19 Elderly Medicine and Frailty

Read more less

Book SynopsisMedicinal Chemistry teaches essential concepts by focusing on how the field is actually practiced, melding real-world research experience with basic principles and modern methods. Written by practicing medicinal chemists, this textbook is intended for advanced undergraduates and first-year graduate students in biology, chemistry, and biochemistry. Pre-medical or pre-pharmacy students and professionals entering the drug discovery field will also find it a useful reference. Building on a foundation of synthetic organic chemistry and structural biology, the book interweaves therapeutics, case studies, historical context, and techniques for discovering, developing, and optimizing new drugs. Chapters are richly illustrated and include problems and annotated journal references with accompanying exercises and answers. Authored by practicing medicinal chemistsâmelding real-world research experience with basic concepts and up-to-date methods Flexible in presentationâ the first five chapters provide a conceptual foundation and historical understanding of the field; subsequent chapters explore the application of concepts. Chapters can be assigned in order of instructor preference and desired emphasis Presents easy-to-follow tables and descriptions of assays next to their relevance to medicinal chemistry and drug discovery, along with target valuesâinformation rarely found all in one place, but is a crucial reference Case studies and Journal Club use current literature to apply concepts from the text to real-life examples. They are also suitable for flipped classrooms and self-study Table of ContentsPART I: Drug Discovery and Development 1. Historical Perspective and Overview of Drug Discovery 2. Drug discovery: Hit and Lead Discovery 3. Drug Discovery: Optimization of Lead Properties PART II: Classes of Drug Targets 4. Medicinal Chemistry Strategies Used in Lead Optimization 5. The Process of Developing a Drug from an Optimized Lead 6. Receptors as Drug Targets 7. Enzymes as Drug Targets 8. Protein-Protein Interactions and Lipids as Drug Targets 9. DNA and RNA as Drug Targets PART III: Selected Therapeutic Areas 10. Anti-Cancer Drugs 11. Infectious Diseases I: Antiviral and Antifungal Drugs 12. Infectious Diseases II: Antibacterial and Antiparasitic Drugs 13. Drugs Acting on the CNS

Read more less

Book SynopsisMaking Medicines is a concise, chronological discussion of the history of therapeutics and pharmacy from the Egyptians through to the present day. It focuses on the discovery and uses of medicines to treat illness through the ages, and the evolving role of the pharmacist.Trade Review'From the Egyptians to present-day, the reader will find a chronological discussion about the discovery and uses of medicines to treat illness. There are two sections that illustrate how pharmacy has developed and evolved over the years. Edited by Stuart Anderson, this book will appeal to a large audience and deliver unique content to you, the reader.'International Journal of Pharmaceutical Compounding, Volume 4. Issue 51. December 28, 2007 * International Journal of Pharmaceutical Compounding *'...an interesting read for the public, students, and those who want to find out more about the history of pharmacy. Although the title of the text suggested it was a "brief" history, it was clear to me that an extensive amount of information was compiled through many different resources.'Megan Thompson, Pharm.D. College of Pharmacy, University of New Mexico, Drug Development and Industrial Pharmacy, 32:909, 2006 -- Megan Thompson * Drug Development and Industrial Pharmacy *'Making Medicines merits a place in any library that shelves a historical collection about the field of health...'Pharmacy in History 48 (3), 148-149 * Pharmacy in History *Table of ContentsPart 1: The Development of Pharmacy: 1. Pharmacy in the Ancient World Up to 1231 AD: William Court; 2. Pharmacy in the Mediaeval World 1231 to 1617 AD: Juanita Burnby; 3. Pharmacy in the Early Modern World 1671 to 1841 AD: Peter M Worling; 4. Pharmacy in the Modern World 1841 to 1986 AD: John A Hunt; Part 2: The Practice of Pharmacy: 5. Pharmacy Education: Melvin Earles; 6. Retail Pharmacy Practice in UK: Peter G Homan; 7. Pharmacy Practice in Hospitals: Shirley Ellis; 8. The Growth of the Pharmaceutical Industry: Judy Slinn; Part 3: The Products of Pharmacy: 9. A History of Therapeutic Discovery: Walter Sneader, Viviane Quirke; 10. A History of Dosage Form: William A Jackson; 11. A History of Drug Safety: 12. From Secret Remedies to Prescription Medicines: Part 4: Pharmacy Today and Tomorrow: 13. Pharmacy Today: Nicholas Wood; 14. Pharmacy Tomorrow: David Taylor

Read more less

Book SynopsisA revision guide for students giving bullet points of basic information on physical pharmacy. This text is derived from the textbook Physicochemical Principles of Pharmacy and is designed to be used alongside it for those revision periods when time is short.Trade Review"A clear summary of the basics, essential for the development of a strong foundation." Dr David Mountford, King's College London, June 2013. -- Dr David MountfordTable of Contents1. Solids 2. Solid dosage forms 3. Solubility and solution properties of drugs 4. Drug stability 5. Surfactants 6. Emulsions, suspensions and other dispersed systems 7. Polymers 8. Drug absorption and delivery 9. Paediatric and geriatric medicines 10. Physicochemical drug interactions and incompatibilities 11. Adverse events – the role of formulations and delivery systems 12. Peptides, proteins and monoclonal antibodies 13. Pharmaceutical nanotechnology 14. In vitro assessment of dosage forms 15. Generic medicines and biosimilars

Read more less

Book SynopsisGuide to cultivating peyote and other psychoactive cacti and extracting active properties, including obtaining seeds, growing a variety of cacti, cloning, and grafting, and extracting the maximum output of mescaline and other alkaloids, descriptions of procedures used for extracting mescaline from peyote and San Pedro, and legal aspects prepared by Attorney Richard Glen Boire.

Read more less

Book SynopsisIn this book we present recent studies that have been carried out on some widely used medicinal plants. The need for new and alternative treatments stem from the lack of efficiency of existing remedies for certain illnesses. We have compiled information that may be useful to researchers in their quest to develop new drugs.Table of ContentsPart 1: Ethnobotany 1. The Genus Aloysia Paláu (Verbenaceae) in Argentina. A Paradigm in Ethnobotany 2. Ethnobotany of Medicinal and Sacred Plants with Ethnopharmacological Potential from Southwestern Colombia 3. Ethnobotanical Uses and Potential Pharmaceutical Applications of the Cactaceae Family 4. Traditional Use of Plants in Mexico for the Treatment of Diabetes: An Ethnopharmacological Review and Scientific Evaluations 5. Limits and Risks of Plants Valorization in Morocco Associated with Their Vernacular Names 6. Resilience of Mapuche Health System and the Influence of COVID-19 Part 2: Traditional Knowledge of Useful Plants 7. Medicinal Use of the Plants of the Atacama Desert 8. Local Botanical Knowledge of Plants Associated with Andean and Chinese Traditions in the Metropolitan Area of Buenos Aires (Argentina): An Urban Ethnobotany Study 9. Traditional Uses, Phytochemistry, and Pharmacology of Mopane (Colophospermum mopane) in Southern African Countries 10. Traditional Medicine of the Kichwa of the Upper Napo 11. Traditional Practices Regarding the Use of Botanicals to Treat Bovine Haemonchosis in Pakistan

Read more less

Book SynopsisBiologics and Biosimilars: Drug Discovery and Clinical Applications is a systematic integration and evaluation of all aspects of biologics and biosimilars, encompassing research and development, clinical use, global regulation, and more. Biosimilars are biological therapeutic agents designed to imitate a reference biologic with high similarities in structure, efficacy, and safety, but also with potential clinical effective and cost-efficient options for the manufacturers, payers, clinicians, and patients. Most of the top-selling prescription drugs in the current market are biologics, which have revolutionized the treatment strategies and modalities for life-threatening and/or rare diseases.This book outlines the key processes and challenges in drug development, regulations, and clinical applications of biologics, biosimilars, and even interchangeable biosimilars. Global experts in the field discuss essential categories and prototype drugs of biologics and biosimilars

Read more less

Book SynopsisThis unique resource provides a comprehensive guide to the evolving regulations and standards which govern the international pharmaceutical industry. Featuring clear explanations of the latest regulations, as well as insights and strategies to maintain compliance, the book covers the key principles of best-practice for laboratory research, manufacturing and distribution. It also offers strategies to navigate the intricacies of different regulatory environments so that pharmaceutical companies can operate internationally, avoiding the potentially costly risk of violations. Detailed and holistic, the book will be an essential resource to pharmaceutical researchers and manufacturers, as well as an important resource for students and scholars in the field.

Read more less

Book Synopsis

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisA definitive and authoritative guide to drugs and why we get high from the creator of the top-rated podcast, Say Why to Drugs. Drugs. We''ve all done them. Whether it''s a cup of coffee or a glass of wine, a cigarette or a sleeping pill. But how well do we understand the effects of the drugs we take - legal or illegal? Say Why to Drugs investigates the science behind recreational drugs- debunking common myths and misconceptions, as well as containing the most recent scientific research. Looking at a range of drugs, this book provides a clear understanding of how drugs work and what they''re really doing to your mind and body. Along the way you will find out why ketamine is on the WHO''s list of essential medicines, why some researchers hope MDMA could treat PTSD, and much more. Enlightening, entertaining, and thought-provoking, Say Why to Drugs is a compelling read that will surprise and educate proponents on both sides of the drugs debatTrade ReviewSuzi Gage cuts through all the sensationalism and goes straight into an erudite, evidence based breakdown. In an area where factual accuracy is often rejected in favour of moralising or panicking this book is a vitally useful and frequently fascinating. -- Robin InceAn essential read. Drugs have a huge impact on our society. Whether you're taking them on not, it's good to be informed. -- Tim LovejoyAn excellently written, ironically clear-headed, and much needed book... that tells you all the important stuff worth knowing about drugs. -- Dean Burnett, author of The Idiot Brain and The Happy Brain It's so refreshing to read a book about drugs which fully acknowledges the complex, nuanced psychological aspects of addiction and that we're all somewhere on that scale. Written without making sweeping moral judgements and faithful to the science, this is a great overview for anyone who wants to educate themselves on a massive (and often emotive) topic. -- Natasha Devon, LBC

Read more less

Book SynopsisCancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trialTrade Review"This book is highly recommended for readers searching for an introductory text to the world of health economic analysis. The authors provide timely examples from both clinical trials in oncology and subsequent real-world application, discussing implications of findings and how they could potentially be applied to make future trials and real-world applications more efficient. ~Nuru Noor, ISCB NewsTable of ContentsContentsPreface......................................................................................................................xvAcknowledgments.............................................................................................. xviiAcronyms and Abbreviations............................................................................ xix1 Introduction to Cancer....................................................................................11.1 Cancer......................................................................................................11.2 Epidemiology of Cancer........................................................................11.2.1 Cancer Trends............................................................................21.3 Prognostic Factors Associated with Cancer Outcomes ...................51.4 Economic Burden of Cancer.................................................................61.4.1 Health Expenditure..................................................................61.4.2 Healthcare Expenditure on Drugs.........................................71.5 Treatments for Cancer......................................................................... 101.6 Important Economic Concepts for Cost-Effectiveness ofCancer Interventions......................................................... 121.6.1 Economics, Health Economics, Economic Evaluation,and Pharmacoeconomics .................................................. 121.6.1.1 Value ......................................................................... 131.6.1.2 Allocative Efficiency............................................... 141.6.1.3 Technical Efficiency................................................ 151.6.1.4 Opportunity Cost.................................................... 161.6.1.5 Discounting.............................................................. 171.6.1.6 The Incremental Cost-Effectiveness Ratio .......... 181.6.1.7 The Cost-Effectiveness Plane................................. 191.6.1.8 Quality-Adjusted Life-Years (QALY) ...................221.7 Health Economic Evaluation and Cancer DrugDevelopment in Practice .........................................................................231.7.1 The Modern Paradigm................................................................... 241.8 Efficacy versus Effectiveness .............................................................261.9 Real-World Data ..................................................................................271.10 Economic versus Clinical Hypotheses .............................................291.11 Summary............................................................................................... 321.12 Exercises for Chapter 1........................................................................332 Important Outcomes for Economic Evaluation in Cancer Studies......352.1 Introduction .........................................................................................352.2 Important Common, Surrogate, and Novel Cancer Endpoints............... 362.2.1 Overall Survival......................................................................362.2.1.1 OS and Economic Evaluation ............................... 412.2.2 Surrogate Endpoints...............................................................462.3 HTAs with Surrogate Endpoints.......................................................532.4 Emerging Tumor-Centered Endpoints.............................................552.5 Demonstrating Value from Other Cancer Endpoints..................... 572.6 Summary...............................................................................................582.7 Exercises for Chapter 2........................................................................583 Health-Related Quality of Life for Cost-Effectiveness.......................... 593.1 Health-Related Quality of Life (HRQoL) in Cancer Patients......... 593.1.1 Limitations of Anti-Cancer Treatments...............................593.1.2 Why Collect HRQoL Data?....................................................603.1.3 Challenges with HRQoL in Cancer Studies........................ 613.2 Measuring Health-Related Quality of Life Outcomes forCommon Cancer Types .................................................................623.2.1 Condition-Specific Measures of HRQoL ............................ 623.2.2 Common General Condition-Specific Measures ofHRQoL in Cancer......................................................................................633.3 Measuring HRQoL for Economic Evaluation ................................. 673.3.1 EuroQol EQ-5D-3L and 5L....................................................683.3.2 EuroQol EQ-5D-5L................................................................. 693.4 Constructing Utilities.......................................................................... 703.5 Quality-Adjusted Life-Years (QALYs)................................................723.5.1 QALY Calculation in Cancer Trials......................................733.6 Economic Evaluation in the Absence of Utility Data:Mapping and Utility Studies ................................................................. 743.7 Sensitivity and Responsiveness of EQ-5D versus QLQ-C30HRQoL for Detecting Improvement in Cancer Patients ...................... 763.8 Measuring Post-Progression (PP) Utility: Some Approaches .......77Why Is Estimation of Utility between Disease Progressionand Death Relevant?............................................................... 78The Behavior of Utility in Cancer Patients betweenProgression and Death?.........................................................793.8.1 Plausible Post-Progression Utility Behavior ......................803.8.2 Non-Linear Models.................................................................823.9 HRQoL issues in Health Technology Appraisals of CancerDrugs .........................................................................................................873.10 Summary...............................................................................................893.11 Exercises for Chapter 3........................................................................894 Introductory Statistical Methods for Economic Evaluation inCancer............................................................................................................... 914.1 Introduction.......................................................................................... 914.2 Uncertainty and Variability................................................................ 914.2.1 Uncertainty..............................................................................924.2.2 Variability.................................................................................924.2.2.1 Hypothesis Testing.................................................934.3 Distributions: Cost, Utility, and Survival Data ...............................934.4 Important Measures Used in Cancer Trials.....................................954.4.1 Time-to-Event Endpoints.......................................................954.4.2 Median Survival.....................................................................964.4.3 Hazard Rate and Hazard Ratio............................................984.4.4 Hazard Ratio............................................................................994.4.5 Survival Rates and Proportions.......................................... 1014.4.6 Relationship between Hazard Rate and Survival Rate......1024.4.7 Transition Probability and Matrix...................................... 1034.4.8 Relation between Transition Probability andSurvival Rates .............................................................................. 1044.4.9 Proportional Hazards.......................................................... 1064.4.10 Mean Survival and Restricted Mean ................................ 1064.5 Simulation: Bootstrapping and Monte-Carlo Simulation............ 1094.5.1 Simulating Using Monte-Carlo Sampling......................... 1114.6 Analyzing Data from Cancer Trials................................................ 1114.6.1 Semi-Parametric Methods: The Cox PH Model............... 1114.6.1.1 Adjusting for Covariates with the Cox Model......1124.6.1.2 Using Hazard Ratios to Predict Survival Rates.....1134.6.2 Parametric Methods: Modeling Survival Data forExtrapolation ........................................................................... 1144.6.3 Advanced Modeling Techniques for Survival Data ....... 1184.6.3.1 Flexible Parametric Survival Models................. 1184.6.3.2 Applications in Cancer Surveillance ................. 1194.7 Issues in Fitting Models....................................................................1224.8 Handling Crossover, Treatment Switching, andSubsequent Anti-Cancer Therapy ............................................. 1234.8.1 Introduction to Treatment Switching................................. 1234.8.2 Types of Switching ............................................................... 1244.8.3 Implications of Switching.................................................... 1244.8.4 Handling Switching in Statistical Analyses .................... 1264.8.4.1 Intent-to-Treat (ITT)............................................... 1274.8.4.2 Per Protocol Analysis............................................ 1284.8.4.3 IPCW....................................................................... 1284.8.4.4 RPFSTM.................................................................. 1294.8.4.5 Two-Stage Adjustment Model ............................ 1314.8.4.6 Other Approaches: StructuralNested Mean Models (SNNM) ............................................................. 1314.9 Data Synthesis and Network Meta-Analyses................................ 1324.9.1 Mixed Treatment Comparisons ......................................... 1324.9.1.1 Direct Comparison................................................ 1334.9.1.2 Indirect Treatment Comparison (ITC) .............. 1334.9.1.3 Meta-Analysis ....................................................... 1344.9.1.4 Network of Evidence ........................................... 1344.9.2 Assumptions for Carrying Out MTCs .............................. 1344.10 Summary............................................................................................. 1384.11 Exercises for Chapter 4...................................................................... 1405 Collecting and Analysis of Costs from Cancer Studies...................... 1415.1 Types of Costs Typical of Cancer Trials.......................................... 1415.1.1 Categorization of Health Resource Use............................. 1425.1.2 Resource Use Monitoring.................................................... 1425.1.3 Baseline Characteristics and Health Resource Use......... 1435.1.4 Costs Determined by a Study Protocol.............................. 1445.2 Perspective of Analysis and Costs Collection................................ 1455.3 Collecting Health Resource Use across the TreatmentPathway ....................................................................................... 1465.3.1 Time Horizon ....................................................................... 1485.4 Costing Methods: Micro versus Macro Approach........................ 1505.4.1 Average versus Marginal and Incremental Cost.............. 1515.4.2 Inflation.................................................................................. 1525.4.3 Time Preference and Discounting...................................... 1535.5 Charges................................................................................................ 1545.5.1 Cost-to-Charge Ratios.......................................................... 1555.5.2 Other Non-Medical Costs (e.g. Societal Costs)................. 1555.6 Distribution of Costs.......................................................................... 1555.6.1 Transforming Cost Data....................................................... 1575.7 Handling Censored and Missing Costs ........................................ 1585.7.1 Strategies for Avoiding Missing Resource Data .............. 1605.7.2 Strategies for Analyzing Cost DataWhen Data Are Missing or Censored ..................................... 1605.7.3 Imputation Methods............................................................. 1615.8 Handling Future Costs...................................................................... 1625.9 Case Report Forms and Health Resource Use............................... 1645.10 Statistical Analyses of Costs ............................................................ 1655.11 Summary............................................................................................. 1725.12 Exercises for Chapter 5...................................................................... 1736 Designing Cost-Effectiveness into Cancer Trials................................. 1756.1 Introduction and Reasons for Collecting EconomicData in a Clinical Trial ........................................................................... 1756.2 Clinical Trial Designs for Cancer Studies...................................... 1786.2.1 Clinical Trial Designs........................................................... 1786.2.2 Interim Analyses and Data Monitoring Committees(DMC)..................................................................................... 1886.3 Planning a Health Economic Evaluation in a Clinical Trial ....... 1916.3.1 Important Considerations When Designinga Cancer Study for Economic Evaluation ............................................... 1916.3.2 Integrating Economic Evaluation in a Clinical Trial:Considerations .......................................................................... 1946.3.3 Endpoints and Outcomes.................................................... 1966.3.3.1 Timing of Measurements..................................... 1986.3.3.2 Trial Design............................................................ 1986.3.3.3 CRF Design............................................................ 1996.3.3.4 Sample Size Methods for Cost-Effectiveness....... 1996.3.3.5 Sample Size Formulae forCost-Effectiveness: Examples .................................................... 2016.3.4 Treatment Pathways.............................................................2046.3.5 Time of Generic/Competition Entry..................................2046.3.6 Treatment Compliance.........................................................2056.3.7 Identify Subgroups/Heterogeneity....................................2066.3.8 Early ICER/INMB.................................................................2066.3.9 Multicenter Trials.................................................................. 2076.4 Case Study of Economic Evaluation of Cancer Trials................... 2106.4.1 TA516 Cabozanitib + Vandetanib....................................... 2106.5 Summary............................................................................................. 2106.6 Exercises for Chapter 6...................................................................... 2137 Models for Economic Evaluation of Cancer........................................... 2157.1 Types of Health Economic Models.................................................. 2157.2 Decision Tree Models........................................................................ 2157.2.1 Further Possible Improvements to theDecision Model ......................................................................................2247.3 Markov Models..................................................................................2267.4 Continuous Time Markov Models...................................................2307.5 The Partitioned Survival Model...................................................... 2317.5.1 Developing an Economic Model Using Patient-LevelData Using a Partitioned Survival Model Approach ......................... 2317.5.1.1 Modeling the Efficacy Data (Survival Data)............................ 2317.5.2 Case Study of an Economic Model Using Patient-Level Data: A Partitioned Survival Model..................................................... 2327.5.3 Crossover...............................................................................2367.6 Summary of Cost-Effectiveness Models for CancerUsed in HTA Submissions ....................................................................2397.7 Summary............................................................................................. 2437.8 Exercises for Chapter 7...................................................................... 2438 Real-World Data in Cost-EffectivenessStudies on Cancer ....................................................................................... 2498.1 Introduction to Real-World Data..................................................... 2498.2 Using RWD to Support Cost-Effectiveness Analysis ................... 2518.3 Strengths and Limitations of Using RWD to SupportCost-Effectiveness Analysis .....................................................2538.3.1 Limitations.............................................................................2558.3.2 Internal Validity versus Generalizability..........................2568.4 Sources for RWD Generation........................................................... 2578.4.1 Registries ...............................................................................2608.4.2 Audits .................................................................................... 2618.4.3 Primary Care Databases: CPRD, THIN, QResearch........ 2628.4.4 Insurance Claims Databases...............................................2638.4.5 Digital Data Sources, Social Media and Applications....... 2638.4.6 Commercial Data Sources...................................................2648.4.7 Pragmatic Clinical Trials.....................................................2648.4.8 Prospective Observational Research Studies...................2658.4.9 Case Control Studies............................................................2658.5 Using Cancer Registries....................................................................2658.5.1 Examples of Registries in the UK for RWE ...................... 2678.6 Statistical Analyses of RWD: Addressing Selection Bias.............2688.6.1 Propensity Score Modeling.................................................2688.6.2 Instrumental Variable Methods.......................................... 274Results..................................................................................................2778.7 Summary and Conclusion................................................................ 2798.8 Exercises for Chapter 8...................................................................... 2819 Reporting and Interpreting Results of Cost-EffectivenessAnalyses from Cancer Trials.....................................................................2839.1 Interpreting Incremental Costs and QALYs...................................2839.1.1 Informative Censoring.........................................................2849.2 Interpreting Incremental QALYs..................................................... 2879.3 Relationship between Costs and QALYs........................................2909.4 Interpreting the ICER and the Cost-Effectiveness Plane.............. 2929.4.1 Uncertainty............................................................................ 2929.5 Presenting and Interpreting Results from UncertaintyAnalysis ....................................................................................................2969.6 Bayesian Sensitivity Analysis...........................................................3069.6.1 Limitations of the ICER and Using the INMB..................3079.7 Presenting and Interpreting Results from Value ofInformation Analyses .............................................................................3089.8 Challenges of VOI Analysis in Healthcare Decisions................... 3169.9 Summary ............................................................................................ 3179.10 Exercises for Chapter 9...................................................................... 317Technical Appendix for Chapter 9.............................................................. 318A9.1 Simulation.............................................................................. 318A9.2 Bayesian PSA......................................................................... 319A9.3 Value of Information............................................................ 320Before Any Data Is Observed........................................................... 321After Data Have Been Observed...................................................... 32110 Factors Predictive of HTA Success and the Global Landscape.......... 32310.1 Introduction........................................................................................ 32310.2 Cancer Drugs Rejected by NICE...................................................... 32310.3 Summary of Criticisms of Economic Models of Cancer.............. 32410.4 Factors Predictive of Successful HTAs in Cancer..........................33510.5 The Changing Pace of the Reimbursement Environment .......... 34110.6 Reimbursement and Payer Evidence RequirementsAcross Different Countries ...........................................................34410.6.1 Canada....................................................................................34510.6.2 France......................................................................................34510.6.3 Germany.................................................................................34610.6.4 Italy.........................................................................................34710.6.5 Spain.......................................................................................34710.6.6 Australia.................................................................................34810.6.7 United Kingdom...................................................................34910.7 Pricing and Reimbursement Environment in theUnited States.......................................................................................34910.8 Value-Based Pricing (VBP) for Cancer Drugs................................35010.9 Risk-Sharing Scheme ........................................................................ 35210.10 The Future of Cost-Effectiveness of Cancer Treatments..............35610.10.1 Future Research: Methodology..........................................35610.10.2 Future Reimbursement Landscape....................................358Budget Impact Threshold................................................... 35910.10.2.1 Automatic Funding for Highly SpecializedDrugs for Rare Diseases.....................................................35910.10.2.2 Fast-Track Appraisals......................................... 35910.11 Summary.............................................................................................36010.12 Exercises for Chapter 10....................................................................360References............................................................................................................ 361Additional Bibliography.............................................................................. 394Chapter 1............................................................................................. 394Chapter 3............................................................................................. 395Chapter 4............................................................................................. 395Chapter 5............................................................................................. 399Chapter 7............................................................................................. 399Chapter 9............................................................................................. 399Index...................................................................................................................... 401

Read more less

Book SynopsisAlthough the non steroidal anti-inflammatory agent diclofenac is an old drug, there is ongoing research interest on potential novel indications of the drug, on adverse drug reactions of diclofenac and on the management of these adverse drug reactions. This book aims to contribute knowledge on novel aspects of the pharmacology of diclofenac. Thus, the book provides evidence on three fields: (i) potential novel indications of diclofenac, especially in oncology, (ii) adverse events of diclofenac and (iii) modulation of gastrointestinal and cardiovascular toxicity of diclofenac. The book is focused on the above areas, contributing evidence on: the anticancer effects of diclofenac; the modulation of stress response by diclofenac; rare severe adverse reactions of diclofenac; thyroid effects of diclofenac; maternal and foetal adverse reactions of diclofenac and the modulation of gastrointestinal; the modulation of cardiovascular toxicity of diclofenac. All the chapters are well-written and structured and appropriately referenced. The authors present their own research work and at the same time they provide a well-informed literature review. The book will be interesting for researchers with interest in diclofenac, academic teachers, medical doctors, pharmacologists, pharmacists, and medical students.Table of ContentsPrefaceAnticancer Effects of Diclofenac: A Multitarget ApproachTargeting Stress Response with DiclofenacDiclofenac and Severe Adverse ReactionsThyroid Effects of DiclofenacThe Use of Diclofenac in Pregnancy: Fetal and Neonatal EffectsThe Use of Diclofenac in Obstetrics and Gynecology: Indications, Efficacy and Adverse EffectsNovel Approaches to Manage Toxicity of Diclofenac in the Gastrointestinal TractMitochondrial and Proteasomal Dysfunction as a Possible Mechanism of Cardiovascular Toxicity of DiclofenacIndex.

Read more less

Book SynopsisPrinciples of Pharmacology for Athletic Trainers, Third Edition continues the tradition of past editions to provide applications of pharmacological principles specifically aimed at the athletic trainer. The drug categories that are included are primarily those that may be pertinent to the treatment of athletic injuries or that may affect athletic performance.Drs. Joel Houglum, Gary Harrelson, and Teresa Seefeldt have taken a unique aspect to the organization and design of the Third Edition to be instructional discussions regarding the use and effects of drugs and of the disease states treated by these drug categories. Additionally, there is a specific discussion of the role of the athletic trainer regarding the therapeutic use and effects of these drugs.Features of the Third Edition: Satisfies all of the CAATE Educational Competencies on pharmacology Advanced organizers and specific learning objectives at the beginning of each chapter Summaries after each major topic within the chapter Case studies and clinical applications Discussion on popular fitness supplements Key words are in italics and defined in the glossary Concept maps present important, yet complex, processes in a concise, graphical way Shaded textboxes throughout include additional information and are beneficial for the reader to recall a key concept addressed in an earlier chapter New ancillary materials specifically for faculty that include PowerPoint slides and test bank questions for each chapter Instructors in educational settings can visit www.efacultylounge.com for additional materials to be used for teaching in the classroom.Principles of Pharmacology for Athletic Trainers, Third Edition will continue to be the go-to resource to determine the best pharmacological treatment strategy and management by athletic trainers.Trade Review“This is a very useful book for athletic training students. Traditionally they would have to use books that didn't focus on the profession of athletic training and would be much more difficult to follow. The book is unique in carving out the most common drug therapies seen in athletic populations and providing basic principles of the effects of using any pharmacologic agent. It also does a great job outlining federal law and the degree to which it is legal for athletic trainers to dispense. All areas are covered with just enough detail for athletic trainers to be able to devise a protocol for their specific location or practice. This update is necessary because of the changes in the law and in the profession, as well as newer concepts such as pharmacogenetics.” - Mary E. Vander Heiden, MA, ATC, LAT, University of Central Florida,Doody’s Review ServiceTable of ContentsDedicationAbout the AuthorsContributing AuthorsPreface Chapter 1 Introduction to Pharmacology Chapter 2 Pharmacokinetic Principles: Processes That Affect Drugs From Entry to Exit Chapter 3 Pharmacodynamic Principles: Mechanism of Drug Action and Therapeutic Considerations Chapter 4 Medication Management in an Athletic Training Facility Alan D. Freedman, MEd, ATC Chapter 5 Drugs for Treating Infections Chapter 6 Drugs for Treating Inflammation Chapter 7 Drugs for Treating Pain Chapter 8 Drugs for Relaxing Skeletal Muscle Chapter 9 Drugs for Treating Asthma Chapter 10 Drugs for Treating Colds and Allergies Chapter 11 Drugs for Treating Gastrointestinal Disorders Chapter 12 Drugs for Treating Hypertension and Heart Disease Chapter 13 Drugs for Treating Psychiatric Disorders Chapter 14 Drugs for Treating Diabetes Mellitus Chapter 15 Herbal and Fitness Supplements Chapter 16 Performance-Enhancing Drugs Michael Powers, PhD, ATC, CSCS, EMT Chapter 17 Drug Testing in Sports Cindy Thomas, MS, AT-R and Nathan Burns, MS, ATC Pharmacological AbbreviationsGlossaryFinancial DisclosuresIndex

Read more less

This fourth edition of How Drugs Work equips readers with a set of clear concepts for matching the pharmacology to the diagnosis, and has been completely revised and updated to reflect the latest knowledge and terminology. Rather than providing overwhelmingly comprehensive information, it condenses the aspects of pharmacology directly relevant to everyday practice into a concise, accessible volume, including material on the half life of drugs, patient non-compliance and severe chronic inflammation.

Read more less

Book SynopsisSynergistic blending is at the very core of aromatherapy practice. This book explores the concept of synergy and the evidence for its presence and significance, and provides practical guidance on how to build aromatherapeutic blends effectively and safely based on research evidence.The author covers new and exciting developments in research into the use of essential oils, explores the merits and limitations of holistic, psychosensory and molecular approaches to blending and suggests effective ways of choosing the most suitable approach for individual clients. Evidence-based profiles of essential oils and absolutes are included and the comprehensive tables summarising their actions enable practitioners to identify easily potential contenders for synergistic blends.Throughout the book, the author encourages students and practitioners of all levels to reflect on their practice, appraising the intended outcomes of their blends and treatment plans, so that they can emerge more knowledgeable and insightful practitioners.Trade ReviewThe wealth of information on essential oils contained within this book make it an indispensable reference for all aromatherapists, and others interested in essential oils. Jennifer Rhind draws from her many years of study, experience and exploration, and combines her insights with a rigorous scientific understanding to shed new light on the actions and character of individual essential oils, together with ideas on how best to combine them into therapeutic blends. Highly recommended. -- Gill Farrer-Halls, LLSA, MIFA, author of 'The Spirit in Aromatherapy' and 'The Aromatherapy Bible'In Aromatherapeutic Blending, Jennifer Rhind explores this fascinating subject from a variety of angles, including up-to-date scientific data, the bio-chemical interaction of essential oils, individual case studies and her own experiential expertise. The material detailed in Part II, Essential Oils & Absolutes: Actions & Evidence, presents a unique contribution to aromatherapy literature and provides a valuable resource for all those involved in creating effective synergy blends. I can highly recommend this book as a well-researched reference source, as well as a practical guide to blending. -- Julia Lawless, aromatherapist, author of 'The Encyclopedia of Essential Oils' and Managing Director of Aqua OleumAromatherapeutic Blending is a book that every aromatherapy practitioner should own and every aromatherapy educator should incorporate into their curriculum. The author takes you on a journey that encompasses and reviews various approaches to aromatherapetic blending and then compares and contrasts them. She provides a summary of relevant discussion of what we (as aromatherapists) have learned from many teachers and schools of thought over time; including various models of client assessment, blending and care. What is refreshing is that alongside the chemistry and biology, the author encourages the reader to discover (or renew) their relationship with plants and the personality and aromatic impact of the essential oils they provide. This book is not a "re-telling" of information, but rather a presentation of many approaches to provide a meaningful exploration, leaving it to the reader to determine what fits best into his/her holistic practice. In addition to providing current information to support the text, she provides key reflective points serving as a catalyst for a dynamic discussion between teacher and student or between colleagues. This is not a book for passive learners, but rather those who want to fully engage in the process of learning about the essential oils and their therapeutic benefits. -- Lora Cantele, Editor/Publisher of The International Journal of Professional Holistic AromatherapyRhind's enthusiastic approach makes for compelling reading from a scientific and holistic point of view. It is a useful functional aid for inspirational blending and a great reference for evidence-based practice. I would recommend it for students and well-versed aromatherapists alike and will be adding it to my recommended reading list for future aromatherapy students. -- Rachel Langford * International Therapist *[This book] gives the reader a tool, or method, on how to bring these aromas, or essential oils, together in a synergistic blend to address the physical and emotional issues we may experience during life (...) this book gives you some techniques for perfecting aromatherapy blends for such conditions as acne, pain, inflammation, infections, wounds, allergies, anxiety, and depression. -- Sharon Falsetto * NAHA Aromatherapy Journal, Winter 2017.4 *Table of ContentsPreface. Acknowledgements. Introduction. Part I. Principles and Practice. 1. Essential oil synergy. 2. The individual prescription. 3. A spectrum of approaches: science-based, psychosensory and vitalistic paradigms. 4. Aromatherapeutic blending. 5. Applications, carrier media, dosage and ratios. 6. Acne vulgaris: a case study. Part II. Essential oils: Actions and Evidence. 7. Pain and Inflammation: analgesic and anti-inflammatory actions. 8. Smooth Functioning: antispasmodic, vasorelaxant, antihyperlipidemic and anticonvulsant actions. 9. Health Maintenance and Enhancement: antioxidant and anti-cancer actions. 10. Infection and Immunity: antimicrobial and immunomodulant actions. 11. Respiratory Support: expectorant, mucolytic, decongestant and antitussive actions. 12. The Skin and Soft Tissues: wound-healing, anti-allergic and antipruritic actions. 13. The Psyche: anxiolytic, antidepressant and cognition-enhancing actions. Part III. Aromatics. 14. Essential oils and Absolutes: evidence-based practice. 15. Expanded Practice Aromatics: abbreviated profiles for synergistic blending. Afterword. Appendix. Fixed and Macerated Oils in Aromatherapy. Glossary. References. Recommended Texts and Further Reading. Resources.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisEssential Prescribing provides medical students with an easy-to-follow overview of the drugs they are most likely to encounter at medical school and as they start their medical careers. The book benefits from the same landscape format and approach as Scion’s bestselling Essential Examination. Each class of drug is detailed using a common tabular format, based on the following sections: Examples Mode of Action Routes of Delivery Indications, Cautions and Contraindications Interactions Monitoring Side-effects Patient counselling This consistent approach helps the reader quickly find the pertinent information for the common drugs and situations they are likely to come across, so they can become confident of prescribing the correct drugs for the patient in appropriate doses. The book also features a questions and answer section at the end of the book for the reader to assess their knowledge. All medical students and foundation doctors now have to prove their prescribing competence by taking the Prescribing Safety Assessment (PSA). Essential Prescribing not only arms the reader with the key knowledge for the PSA, but also provides them with the core prescribing knowledge they will need as their medical careers progress. The book is also ideal for Independent Prescriber V300 courses.Trade ReviewGreat book with all the common drugs 'I love this book. It’s set up just like Essential Examination (Ruthven) and includes all the common drugs a newly qualified doctor is expected to know, including knowledge to face the PSA. It has lots of mnemonics for every drug which I am personally not a big fan of but that’s only because I don’t learn from mnemonics generally. Really liked the sections on emergency drugs and fluid presc ribing.' Amazon reviewer Easy, concise, systematic guidelines for prescribing essentials of patient care! 'This book is a wealth of information! Well written in a simple concise, easy to follow guidelines for prescribing medications, oxygen, intravenous fluids ...extra and is divided by the system involved and has a section specifically for patient counseling which makes this book unique.' Amazon reviewer Useful 'A straight forward and useful book which gives you the essential info about many common drugs.' Amazon reviewer Good book 'A well written book...good for medical revision!!' Amazon reviewer Table of ContentsPreface; Acknowledgments; Abbreviations General prescribing rules Section I: Prescribing by system 1. Cardiovascular system 2. Haematological system 3. Respiratory system 4. Gastrointestinal system 5. Renal system 6. Endocrine system 7. Female reproductive system 8. Male reproductive system 9. Central nervous system 10. Musculoskeletal system Section II: Prescribing by situation 11. Intravenous fluids 12. Oxygen therapy 13. Antibiotics 14. Analgesia 15. Emergency drugs 16. Prescribing in the elderly Section III: Self-assessment questions and answers 17. PSA-style questions and answers 18. Test your knowledge questions and answers Appendix: Mnemonic acknowledgments Index

Read more less

Book SynopsisA TELEGRAPH BOOK OF THE YEAR. An undercover investigation into the synthetic-drug epidemic. A new group of chemicals is radically transforming the recreational-drug landscape. Known as novel psychoactive substances (NPS), they range from so-called ‘legal highs’ like Spice, to synthetic opioids – most famously, the deadly fentanyl. Designed to replicate the effects of established drugs like cocaine, ecstasy, marijuana, and heroin, NPS are synthesised in laboratories. They are cheap to produce and easy to transport. They are also extremely potent and often deadly. Originally developed for medicinal purposes, and then hijacked by rogue chemists, who change their molecular structures to stay ahead of the law, these chemicals’ effects can be impossible to predict. What we do know is that they have triggered the biggest drug epidemic that America has ever seen, and which is now spreading internationally. In Fentanyl, Inc., award-winning journalist Ben Westhoff goes undercover to investigate the shadowy world of synthetic drugs — becoming, in the process, the first journalist to infiltrate a Chinese fentanyl lab. He tracks down the drug baron in New Zealand who unintentionally helped to start the synthetic-drug revolution; prowls St. Louis streets with a former fentanyl dealer to understand how the epidemic started; and chronicles the lives of addicts and dealers, families of victims, law enforcement officers, and underground drug-awareness organisers in the US and Europe. Fentanyl, Inc. is essential reading on a global calamity we are only just beginning to understand.Trade Review‘It’s a sucker-punch of a read … Westhoff exposes, with cinematic scope and reams of data, a new epidemic.’ -- Harriet Alexander * The Daily Telegraph *‘Groundbreaking.’ -- Eleanor Halls * The Telegraph *‘An eye-opening work of journalism, informed on the legal and pharmaceutical aspects without losing sight of the human cost.’ -- Alastair Mabbott * The Herald *‘A fascinating book.’ -- Seán Moncrieff * The Moncrieff Show *‘Through his courageous reporting, Ben Westhoff takes us to the heart of the problem. In Fentanyl, Inc. he shines a light on the human wreckage and damage caused by the most powerful and dangerous of the opioids, fentanyl, and its derivatives. He shows us how addiction, mislabeling, purposefully or mistakenly mixed drugs lead to tragic ends. The drug is often created out of factories operating with the permission of the Chinese government. To solve this epidemic, we must understand it. Make no mistake; the fentanyl problem is a global issue. Fentanyl, Inc. is a must-read, pulling the curtain back and showing us how this human tragedy occurs and how insidious and addictive a drug can be.’ -- Katherine Tobin, PhD, Former Member of the U.S.-China Economic & Security Review Commission‘A necessary and sobering look at the opioid crisis and how it is not as simple as it appears on the surface. Well-researched and user-friendly for all readers. An important book.’ -- Debra Ginsberg * Bay Books *‘Drawing material from official reports, drug databases, scores of interviews, and years of personal research, Westhoff presents an unflinching, illuminating portrait of a festering crisis involving a drug industry that thrives as effectively as it kills. Highly sobering, exemplary reportage delivered through richly detailed scenarios and diversified perspectives.’ STARRED REVIEW * Kirkus Reviews *‘This is an exceptionally useful and well-timed book. I hope anyone concerned about this era’s new addiction epidemic will read it and put its messages to use. Ben Westhoff very skilfully combines pharmacology, politics, law enforcement, and gripping international intrigue in his account of America’s number-one public health problem. I hope Fentanyl, Inc. is widely read and influential.’ -- James Fallows, award-winning journalist and author of China Airborne‘In Fentanyl, Inc., Ben Westhoff lays bare the twisted history that led to opioids wreaking havoc on twenty-first century America. If you want to understand the bloody cycle of addiction and death gripping the nation, you need to read this book.’ -- Ioan Grillo, author of El Narco and Gangster Warlords‘An information-packed work of reporting that traces the rise of designer drugs, including synthetic and/or more dangerous versions of weed, acid, and heroin, the last of which gives the book its title. Fentanyl, a synthetic opioid that’s chemically similar to morphine and heroin, is the top cause of fatal drug overdoses in the United States. The most illuminating parts of the book are those that reveal the business practices of Chinese labs that supply illicit fentanyl to U.S. dealers. These labs are a source of death and destabilisation for our country, American officials say, while Chinese leaders contend that it’s on us to deal with Americans’ appetite for the stuff.’ -- Francie Diep * Pacific Standard *‘Westhoff explores the many-tentacled world of illicit opioids, from the streets of East St. Louis to Chinese pharmaceutical companies, from music festivals deep in the Michigan woods to sanctioned ‘shooting up rooms’ in Barcelona, in this frank, insightful, and occasionally searing exposé ... Offers a truly multifaceted view of the landscape of fentanyl use and abuse. The disparate narrative strands he weaves together — including tragic stories of drug users, straightforward analysis of the history of opioid use, tension-filled episodes of drug runs and supplier meet-ups, and the humane and hopeful work of the ‘harm reduction’ movement—all come together to provide a more complex understanding of the rise of, and response to, the opioid epidemic. Westhoff’s well-reported and researched work will likely open eyes, slow knee-jerk responses, and start much needed conversations.’ * Publishers Weekly *‘Excellent’ -- Mary Wakefield * The Spectator *‘Will assist policymakers, activists, and general readers in understanding better how to respond to the drug crisis that is only more intractable now.’ * Library Journal *‘So many substance abuse books are a mix of hysterical in tone and a disappointing ‘paint by numbers’ in their execution, but [Fentanyl, Inc.] really stands out for its research, journalism, and overall analysis ... It is also a great book on China, and how China and the Chinese chemicals industry works, backed up by extensive original investigation ... Definitely recommended.’ -- Tyler Cowen * Marginal Revolution *‘Timely and agonising … [Westhoff’s] book is the product of a four-year deep-dive into the world of designer drugs, and it’s an impressive work of investigative journalism. He interviewed 160 people and visited laboratories all over the world; he even infiltrated a pair of Chinese drug operations.’ * USA Today *‘A history lesson on American drug use and drug laws, a crash course in chemistry and neuroscience, a multifaceted portrait of addiction, and a look at how harm reduction programs can atone for the failures of the War on Drugs … A finely woven and accessible analysis of the connection between university chemistry professors, dark web sales, drug cartels, law enforcement, and the dealers and addicts dependent on it … Westhoff is a skilled and empathetic biographer, and this gift serves the composite of the dealers, users, and bereaved of Fentanyl, Inc. … It’s in this focus on the human cost of the crisis, of empathy over criminalisation, that this accomplished book feels most urgently important.’ * St. Louis Post-Dispatch *‘The most frightening book of the year, and it’s mandatory reading … Epic … This is a story about people, and Fentanyl, Inc. features a roster of villains and victims who stray far from movie archetypes.’ * Dig Boston *‘Setting Fentanyl, Inc. apart from most other books that focus on the supply-side of illegal drugs, Westhoff smartly avoids pro-drug-war narratives that push for an intensified law-and-order response to the proliferation of more potent synthetic drugs … The War on Drugs and misguided law enforcement efforts have not stemmed the spread of fentanyl, but instead have contributed to its takeover, Westhoff carefully explains.’ * Filter *‘Extensively reported and vividly written … Westhoff elevates his impressive examination of the opioid epidemic by reporting on the US government’s failed war on drugs and the promise of innovative ‘harm reduction’ policies that recognise that ‘Just Say No’ is a losing proposition.’ * National Book Review *‘Westhoff looks at the new wave of synthetic drugs that are taking the opioid epidemic to a whole new deadly level. He managed to go undercover into one of the many labs in China where these drugs are being manufactured, and the results of his research there and elsewhere are terrifying … Anyone who is interested in learning more about the opioid crisis, or has read Dopesick, is going to want to check this out.’ * Omnivoracious, the Amazon Book Review *‘A detailed and far-ranging investigation into the production, marketing, and usage of fentanyl reveals an intertwined business network that spans continents and kills thousands.’ * Shelf Awareness *‘In this gripping investigation, Westhoff recounts the deadly consequences of synthetically made drugs and how this phenomenon is beginning spread internationally.’ * Happy Mag *‘The way [Fentanyl, Inc.] looked at every aspect of the novel psychoactive substance trade was unique. From chemists manipulating chemical structures of precursors to fentanyl before countries can ban them, to the dealers, end users and those who want to change the way addiction is treated, Westhoff details it all ... this book is an eyeopener to anyone who reads it of just how coordinated and advanced the illicit drug trade is in aiming to get new highs to market at any cost.’ * Sam Still Reading *‘Fentanyl, Inc. is a wake-up call to us all. Shocking and unnerving.’ -- Judith Baragwanath * Noted *‘The information uncovered by Westhoff, an investigative reporter, will no doubt prove useful to lawmakers, addiction counsellors, and anyone else who is dealing with opioid addiction ... But where the book really shines is in Westhoff’s ability to get inside the lives of his characters, from addicts like Henke and Schwandt, to the scientists who initially developed opioids, to the Chinese chemists who are manufacturing fentanyl knockoffs — and profiting hugely off the global rise of opioid addiction ... a feat of reporting, to be sure. And while the many details Westhoff uncovered are likely to leave some readers enraged, Fentanyl, Inc. is an important book that arrives at a key juncture in the opioid crisis.’ -- Arlene Weintraub * The New York Journal of Books *‘[E]pic ... like Breaking Bad, sure — meets Night of the Living Dead meets New Jack City, Gummo, Kids and Gremlins, with a cast from a lot of the places on President Donald Trump’s ‘shithole’ list ... Westhoff includes ample relevant history.’ -- Chris Faraone * Little Village *‘A really fascinating book on a terrifying subject.’ * Joe Rogan *‘Excellent … Readable and alternately engaging and chilling in its account of the development, deployment, and devastating consequences of NPS … Politicians, police, and the public continue to debate how to handle the use of psychoactive substances in our culture and legal system. Westhoff’s Fentanyl, Inc. should be required reading for anyone who wishes to contribute to a knowledgeable discussion.’ * Winnipeg Free Press *‘A fascinating look into how China is playing a major role in the spread of fentanyl across the US. The book connects the dots between the pharmaceutical companies and their role in the opioid crisis with the Chinese labs manufacturing the illicit fentanyl and manoeuvring it through Mexico to get it into the US. Highly recommend it!’ * Yahoo Finance *Praise for Original Gangstas ‘I trust Ben Westhoff. I trust him to report a story and I trust him to tell a story, and that's exactly what he's done here in Original Gangstas. He's taken what's always felt like an almost impossibly knotted string of storylines and plot points in gangsta rap, the most turbulent version of the most popular music on the planet, and turned them into an airtight and unflinching book. Original Gangstas is as resolute as the people and ideas it sets out to profile, and that is no small feat.’ -- Shea Serrano, New York Times bestselling author of The Rap Year BookPraise for Original Gangstas ‘A provocative, multifaceted portrait of essential rap pioneers who ushered the hip-hop music scene to greatness … As raw, authoritative, and unflinching as the music his narrative chronicles, Westhoff comprehensively uncovers the factual roots of the gangsta rap movement and admirably credits those whose footprints paved the way for the younger rappers emerging today … An elaborately detailed, darkly surprising, definitive history of the LA gangsta rap era.’ STARRED REVIEW * Kirkus *Praise for Dirty South ‘Packed with lively reporting and colourful social history … doesn't shy away from the bigger questions. Westhoff grapples with Southern rap's troubling racial politics and takes on the critics.’ * Rolling Stone *

Read more less

Book SynopsisFor half a century the Misuse of Drugs Act 1971 has dominated ill-conceived approaches to the prohibition of drugs and the criminalisation of many offenders. Wilful blindness to scientific facts has distorted the dispensation of justice, prevented lifesaving investigation, sidelined critics and thwarted advocates of politically inconvenient drugs law reform. This once in an epoch review by experts from a range of disciplines shows how lawmakers and the media have ignored the scientific evidence to sustain badly founded rhetoric in favour of blanket bans, punishment and the marginalisation of opponents. Countless individuals (including the vulnerable, deprived, addicted and mentally ill) have therefore suffered unnecessarily. This, the most comprehensive critique of the 1971 Act yet, rests on the combined learning of leading medical, scientific, psychiatric, academic, legal, drug safety and other specialists to provide sound reasons to re-think half a century of bad law.Trade Review'It is time to see the MDA 1971 for what it is: a bad law that has the opposite effect to that intended. The so-called war on drugs is lost. It could never be won. Let us replace this knee-jerk law with something rational, something evidence-based, something more humane.'- From the Foreword.Table of ContentsForeword by The Rt Hon Norman Baker; Introduction. PART I - The Impact Of Drugs: At the Frontiers of Psychiatry; A Forensic Science Perspective; Fifty Years of MDMA; Displacement, Adulteration and Innovation - How the MDA 1971 Failed to Control NPS; Cannabis: Past, Present and Future; Narratives of Drug-related Harm. PART II - Impact on the Medical, Pharmacy and Veterinary Professions: Chronic Pain; The Impact of the MDA 1971 on the Veterinary Profession; Enabling Access to Essential Medicines and Devices. PART III - Legacies of the Drug Laws: How States Have Adapted Their Drug Laws; The Sixties, Barbara Wootton and the Counterculture - Revisiting the Origins of the MDA 1971; The Ongoing Impact on the Racialised Policing of Black Communities. PART IV - Perspectives and Approaches: Challenging Stigma, Changing Minds; The MDA 1971: No Education; The Impact of Drug Legislation on Climate Change; Decision Conferencing and Multi-criteria Decision Analysis; The MDA 1971: Missteps and Misunderstandings. PART V - Changing Policy: Regulating the Legal: Lessons from Alcohol Policy and the Battle for Minimum Unit Pricing in Scotland; A Modest Proposal to Decriminalise the Simple Possession of Drugs; The Legal Regulation of Drugs in the UK. Index.

Read more less

Book SynopsisGet the current, reliable information you need to ace your pharmacology-related assessments and transition confidently to healthcare practice! BRS Pharmacology, 8th Edition, edited by Dr. Sarah Lerchenfeldt and part of the popular Board Review Series, equips medical, advanced practice, and other health professions students with the preparation needed to master the general principles of drug mechanisms,  the details of how drugs act on major body systems, and gain a deep understanding of their indications and potential adverse effects. The BRS format delivers vital information in a succinct, streamlined format preferred by today’s students. Includes core BRS features: simple, easy-to-understand drawings; bolded key concepts; and NBME-style review questionswith answers and explanations to test your understanding, identify weaknesses, and gain familiarity with the exam format Enhances your retention with powerful mnemonics and vibrant illustrations that simplify complex pharmacological concepts, making it easier to recall information and ensuring success from the USMLE to clinical practice Features numerous content updates throughout (including recently approved drugs) and newly revised practice questions online Covers high-yield topics, uses a systems-based organization, and features a concise, outline format Contains convenient drug summary tables, as well as cross references in the Comprehensive Examination that point you to specific content for fast, efficient review

Read more less

Book SynopsisThis open access book provides an extensive review of ethical and regulatory issues related to human infection challenge studies, with a particular focus on the expansion of this type of research into endemic settings and/or low- and middle-income countries (LMICs). Human challenge studies (HCS) involve the intentional infection of research participants, and this type of research is rapidly increasing in frequency worldwide. HCS are widely considered to be an especially promising approach to vaccine development, including for pathogens endemic to LMICs. However, challenge studies are sometimes controversial and raise complex ethical issues, some of which are especially salient in endemic and/or LMIC settings. Informed by qualitative interviews with experts in infectious diseases and bioethics, this book highlights areas of ethical consensus and controversy concerning this kind of research. As the first volume to focus on ethical issues associated with human challenge studies, it sets the agenda for further work in this important area of global health research; contributes to current debates in research ethics; and aims to inform regulatory policy and research practice. Insofar as it focuses on HCS in (endemic) settings where diseases are present and/or widespread, much of the analysis provided here is directly relevant to HCS involving pandemic diseases including COVID19. Table of Contents1. Introduction.- 2. Methods.- 3. History of human challenge studies.- 4. ethical issues.- 5. Community engagement, ethics review, and regulation.- 6. Case studies.- 7. Conclusions.- Acknowledgements.

Read more less

Book SynopsisThis updated and revised textbook presents a broad overview on topics concerning cellular electrophysiology – ranging from bioelectric phenomena recognized as far back as ancient Egypt to popular topics on the dangers of electrosmog. Without sacrificing scientific precision, this clear and concise work presents on the one hand the different methods and modern applications, on the other hand the biophysical fundamentals of ion-channel and carrier proteins. Numerous and carefully selected illustrations and diagrams supplement the text. Each chapter is extended by a detailed table of Take-Home Messages. Questions at the end of each chapter allow readers to test their understanding. Each section also includes references to relevant original literature for further reading. The book offers a valuable resource for students of biology, chemistry and physics with a special interest in biophysics.Table of Contents

Read more less

Book Synopsis

Read more less

Book SynopsisPhytochemical research took shape with the isolation of morphine by F.W. Seturner in 1805. This book includes about 290 phytopharmaceuticals giving their characterization and structure elucidation by modern instrumental methods like UV, IR, HNMR 13C NMR, Ms, HRMS, X-Ray, biosynthesis and synthesis. The book though written for M.Pharm. Pharmacognosy will, however, also found useful as a reference by researchers in natural product chemistry in ICMR units, National Laboratories and pharmaceutical industry the world over.Table of Contents 1. Terpenoids 8. Vitamins and Other Health Products 2. Steroids 9. Antibiotics 3. Flavonoids 10. Lipids 4. Alkaloids 11. Carbohydrates 5. Proteins and Polypeptides 12. Toxins (Aflatoxins) 6. Nucleic Acids 13. Marine Agents 7. Lipoproteins and Amino -Acids

Read more less

Book SynopsisBillions of people worldwide take medicines every day to treat important diseases. In many cases, however, neither the doctor nor the pharmacist has the time to explain to the patient why a particular drug should be taken, how the drug works and what side effects to expect. Of course, the patient can find "everything" about a particular drug on the Internet. But how reliable and understandable is this information? In addition, most Internet sources do not point out the interrelationships between different diseases and drug interactions. Written by an experienced and well-known textbook author, this book provides an overview of the most common diseases and the drugs used to treat them. The book is designed for a general audience. It provides patients with essential information about how medications work and what side effects and interactions to expect. Finally, the book gives patients advice on what they can do themselves to improve drug therapy and safety. Summaries, bullet points, tables and diagrams support the information process.Table of ContentsChapter 1. What Should I Know About Drugs?.- Chapter 2. Painkillers (analgesics).- Chapter 3. Drugs for Gastrointestinal Disorders.- Chapter 4. Drugs for Respiratory Diseases.- Chapter 5. Drugs for Cardiovascular Diseases.- Chapter 6. Drugs for Metabolic Disorders.- Chapter 7. Drugs for Her and Him.- Chapter 8. Drugs for Neurological Disorders.- Chapter 9. Drugs for Mental Disorders.- Chapter 10. Drugs for Eye Diseases.- Chapter 11. Drugs for Cancer and Autoimmune and Infectious Diseases.

Read more less

Book SynopsisWhile palliative care has adopted a holistic approach to treatment, medication driven symptom management ostensibly forms the critical aspect of care. Prescribing in palliative care can be extremely complex because the patient may often have comorbidity, or occasionally multimorbidity. The associated polypharmacy further complicates the pharmacological management of symptoms being caused by the palliative condition. This can be daunting for healthcare professionals and can negatively impact upon the effectiveness of care provided.Fully revised and updated, the third edition of Drugs in Palliative Care provides an accessible and succinct overview of the main drugs that are encountered in palliative care clinical practice. The text begins by providing a clinical pharmacology overview and prescribing guidance, then contains over 160 monographs of palliative care drugs, in an easy to access A-Z format.Trade ReviewReview from previous edition I like the handy pocket-size and the drug monographs are organised in an easy-to-use A-Z format. This book would be very useful as a quick reference on any palliative care unit. * IAHPC Newsletter *Table of ContentsDetailed contents Symbols and abbreviations 1: Clinical pharmacology overview 2: Prescribing guidance 3: Drug Monograph A-Z Index

Read more less

Book SynopsisPharmacy Registration Assessment Questions 4 features more than 400 entirely new, closed book and calculation questions in line with current GPhC guidance. This revision aid gives you the opportunity to practice a variety of question styles found in the assessment including single best answer questions, extended matching questions and calculations.Table of ContentsPrefaceAcknowledgementsAbout the authorsAbbreviations How to use this bookSingle best answer questionsSection ASection BSection CExtended matching questions Section ASection BSection CCalculation questionsSection ASingle best answersExtended matching answersCalculation answers

Read more less

Book SynopsisThe first choice for concise medicines information for children. Practical and evidence-based, BNF for Children (BNFC) is the only child-focused drug formulary in the world that is both independent, and has rigorous, accredited content creation processes. Relied on by health professionals who prescribe, dispense, and administer medicines to paediatrics, BNFC supports confident decision-making at the point of care. including best practice guidelines and advice from a network of paediatric experts. The process is overseen by a Paediatric Formulary Committee. BNFC is published jointly by BMJ Group, Pharmaceutical Press, RCPCH, and NPPG.

Read more less

Book Synopsis

Read more less

Book Synopsis

Read more less

Book SynopsisThis established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.Trade Review"The text is highly illustrated throughout and includes key points and appropriate examples, providing clinicians with some easily accessible and relevant information. Some examples of adverse events due to excipients, impurities, the influence of dosage forms, materials in delivery devices and even light-induced effects are also included. Although the detection of adverse events is not an easy task, these examples may assist clinicians in asking the right questions to predict or identify adverse effects. The new focus on applications to clinical practice in this edition has extended its usefulness from pharmacy and pharmaceutical scientist courses to clinicians seeking an understanding of formulations, especially for children and older people, and in identifying the cause of adverse events."Beverley Glass, Australian Prescriber October 2016 -- Beverley Glass * Australian Prescriber *

Read more less

Book SynopsisMedicinal Natural Products: A Biosynthetic Approach, Third Edition, provides a comprehensive and balanced introduction to natural products from a biosynthetic perspective, focussing on the metabolic sequences leading to various classes of natural products.Trade Review"Students should be empowered for a deductive analysis of the presented substances." (Arzneimittelforschung, December 2009) "This new edition is an excellent text that is unrivaled in both its scope and overall coverage of natural products biosynthesis." (Journal of Medicinal Chemistry, August 2009) "There is no question that this is the best book available on the biosynthesis and bio-organic chemistry of medicinally important natural products." (Education in Chemistry, September 2009)Table of Contents1 About this book, and how to use it 1 The subject 1 The aim 1 The approach 2 The topics 2 The figures 2 Further reading 3 What to study 3 What to learn 3 Nomenclature 3 Conventions regarding acids, bases, and ions 4 Some common abbreviations 4 Further reading 5 2 Secondary metabolism: the building blocks and construction mechanisms 7 Primary and secondary metabolism 7 The building blocks 8 The construction mechanisms 11 Alkylation reactions: nucleophilic substitution 12 Alkylation reactions: electrophilic addition 12 Wagner–Meerwein rearrangements 15 Aldol and Claisen reactions 15 Imine formation and the Mannich reaction 18 Amino acids and transamination 20 Decarboxylation reactions 22 Oxidation and reduction reactions 24 Dehydrogenases 24 Oxidases 26 Monooxygenases 26 Dioxygenases 26 Amine oxidases 27 Baeyer–Villiger monooxygenases 27 Phenolic oxidative coupling 28 Halogenation reactions 28 Glycosylation reactions 31 Elucidating biosynthetic pathways 34 Further reading 38 3 The acetate pathway: fatty acids and polyketides 39 Fatty acid synthase: saturated fatty acids 39 Unsaturated fatty acids 44 Uncommon fatty acids 53 Prostaglandins 58 Thromboxanes 64 Leukotrienes 64 Polyketide synthases: generalities 66 Polyketide synthases: macrolides 68 Polyketide synthases: linear polyketides and polyethers 90 Diels–Alder cyclizations 96 Polyketide synthases: aromatics 96 Cyclizations 99 Post-polyketide synthase modifications 103 Starter groups 116 Further reading 131 4 The shikimate pathway: aromatic amino acids and phenylpropanoids 137 Aromatic amino acids and simple benzoic acids 137 Phenylpropanoids 148 Cinnamic acids and esters 148 Lignans and lignin 152 Phenylpropenes 156 Benzoic acids from C6C3 compounds 157 Coumarins 161 Aromatic polyketides 166 Styrylpyrones, diarylheptanoids 166 Flavonoids and stilbenes 167 Flavonolignans 173 Isoflavonoids 174 Terpenoid quinones 178 Further reading 184 5 The mevalonate and methylerythritol phosphate pathways: terpenoids and steroids 187 Mevalonic acid and methylerythritol phosphate 188 Hemiterpenes (C5) 192 Monoterpenes (C10) 193 Irregular monoterpenes 204 Iridoids (C10) 206 Sesquiterpenes (C15) 210 Diterpenes (C20) 223 Sesterterpenes (C25) 234 Triterpenes (C30) 234 Triterpenoid saponins 242 Steroids 247 Stereochemistry and nomenclature 247 Cholesterol 248 Phytosterols 251 Vitamin D 256 Steroidal saponins 259 Cardioactive glycosides 265 Bile acids 275 Adrenocortical hormones/corticosteroids 277 Semi-synthesis of corticosteroids 277 Progestogens 287 Oestrogens 290 Androgens 296 Tetraterpenes (C40) 298 Higher terpenoids 306 Further reading 306 6 Alkaloids 311 Alkaloids derived from ornithine 311 Polyamines 311 Pyrrolidine and tropane alkaloids 312 Pyrrolizidine alkaloids 324 Alkaloids derived from lysine 326 Piperidine alkaloids 326 Quinolizidine alkaloids 328 Indolizidine alkaloids 330 Alkaloids derived from nicotinic acid 331 Pyridine alkaloids 331 Alkaloids derived from tyrosine 336 Phenylethylamines and simple tetrahydroisoquinoline alkaloids 336 Modified benzyltetrahydroisoquinoline alkaloids 346 Phenethylisoquinoline alkaloids 359 Terpenoid tetrahydroisoquinoline alkaloids 363 Amaryllidaceae alkaloids 365 Alkaloids derived from tryptophan 366 Simple indole alkaloids 366 Simple β-carboline alkaloids 369 Terpenoid indole alkaloids 369 Quinoline alkaloids 380 Pyrroloindole alkaloids 385 Ergot alkaloids 387 Alkaloids derived from anthranilic acid 395 Quinazoline alkaloids 395 Quinoline and acridine alkaloids 396 Alkaloids derived from histidine 398 Imidazole alkaloids 398 Alkaloids derived by amination reactions 400 Acetate-derived alkaloids 401 Phenylalanine-derived alkaloids 401 Terpenoid alkaloids 406 Steroidal alkaloids 406 Purine alkaloids 413 Caffeine 413 Saxitoxin and tetrodotoxin 416 Further reading 417 7 Peptides, proteins, and other amino acid derivatives 421 Peptides and proteins 421 Ribosomal peptide biosynthesis 422 Peptide hormones 426 Thyroid hormones 426 Hypothalamic hormones 427 Anterior pituitary hormones 429 Posterior pituitary hormones 430 Pancreatic hormones 432 Interferons 433 Opioid peptides 434 Ribosomal peptide toxins 434 Enzymes 438 Non-ribosomal peptide biosynthesis 438 Modified peptides: penicillins, cephalosporins, and other β-lactams 458 Penicillins 458 Cephalosporins 465 Other β-lactams 469 Cyanogenic glycosides 476 Glucosinolates 477 Cysteine sulfoxides 480 Further reading 481 8 Carbohydrates 485 Monosaccharides 485 Oligosaccharides 490 Polysaccharides 493 Aminosugars and aminoglycosides 498 Further reading 507 Index 509

Read more less

Book SynopsisThis second edition of Clarke's Analytical Forensic Toxicology offers a fresh perspective on the drugs and poisons that you are most likely to encounter in forensic toxicology, with a focus on collection, extraction and analysis.Trade Review"...a useful reference for students both undergraduate and postgraduate, as well as toxicologists who are relatively new to this discipline...There are many chapters from experienced toxicologists (many who are familiar to us) and the book is well structured and follows a consistent approach to understanding the essentials of forensic toxicology...There is a comprehensive number of chapters on techniques (extraction and analysis) and the major chromatographic approaches are covered well by recognised authors with considerable expertise...So if you have the 4th edition of Clarke's Analysis of Drugs and Poisons would you also buy this volume as well? Yes I would because the book is geared to a more novice readership - students, researchers and inexperienced toxicologists." Dimitri Gerostamoulos, TIAFT Bulletin 43(2), July 2013. -- Dimitri Gerostamoulos * TIAFT Bulletin *"This new edition is based on content in volume 1 of Clarke's Analysis of Drugs and Poisons, and modified for student use...this volume is full of useful information that will allow students to become familiar with the field. Summing up: Recommended. Upper-division undergraduates and graduate students." J. Allison, The College of New Jersey, CHOICE (51:3) November 2013. -- J. Allison * CHOICE *Table of Contents1. Introduction to Forensic Toxicology 2. Pharmacokinetics and Metabolism 3. Drugs of Abuse 4. Other Poisons 5. Workplace Drug Testing 6. Alternative Specimens 7. Postmortem Toxicology 8. Clinical Toxicology 9. Drug Abuse in Sport 10. Drug-Facilitated Sexual Assault 11. Alcohol, Drugs and Driving 12. Forensic Chemistry & Solid Dosage Form Identification 13. Sampling, Storage and Stability 14. Extraction 15. Colour Tests and Thin-Layer Chromatography 16. Immunoassays 17. Ultraviolet, Visible and Fluorescence Spectrophotometry 18. Infrared Spectroscopy 19. Gas Chromatography 20. High-Performance Liquid Chromatography 21. Mass Spectrometry 22. Quality Control and Assessment

Read more less

Book SynopsisTable of Contents1. Introduction2. Fluidization Theory3. Fluid Bed Processor Equipment and Its Functionality4. Process Development5. Granulation6. Drying7. Coating8. Pelletization9. Other Fluid Bed Processes and Applications10. Process Control and PAT11. Process Scale-Up12. Integrated Systems13. Process Troubleshooting14. Fluid Bed Safety

Read more less

Book SynopsisTable of Contents1. Introduction 2. Polysorbate Surfactants used in biopharmaceuticals: An overview including in vivo fate and toxicology perspective 3. Surfactants (polysorbate and poloxamer) synthesis and degradation: Overview and relevance 4. Mechanisms of stabilization of proteins by surfactants 5. Behaviour of surfactant during processing (UF/DF, filter adsorption) 6. Analytical methods for surfactant characterization in Drug Product 7. Oxidative degradation of surfactants: Mechanisms 8. Hydrolytic degradation of surfactants and impact on protein stabilization 9. Regulatory Perspective on Surfactant Monitoring and Control 10. Control strategies to address surfactant degradation: A quality perspective 11. A look to the future - closing remarks

Read more less

Book SynopsisThe completely revised and expanded Student Workbook offers readers more practice and review opportunities that are tied to the learning goals in Focus on Pharmacology: Essentials for Health Professionals , Third Edition. The Workbook contains many different types of review questions, including multiple-choice, fill-in-the-blank, true/false, and critical-thinking.

Read more less

Book SynopsisDrug Design and Development outlines the processes involved in the design and development of new drugs and emphasises the significance of these processes to the practice of pharmacy. The book highlights why it is important that all practicing pharmacists, including those working in hospitals or high street stores, have a solid understanding of the process of the design and development of the drugs they interact with. It adopts an integrated approach, formulated to complement courses which are designed in line with the General Pharmaceutical Council''s new curriculum requirements. Furthermore, this is the only integrated textbook to consider both drug design and development within one volume. Throughout the book, the journey of the drug, from discovery to market, is presented in an integrated fashion, emphasising the interconnection of all the processes involved.Trade ReviewWell written text that guides students through the complex elements of the drug development process. It has a chemistry focus and utilises 'key points' to reinforce the important aspects at regular opportunities. * Dr James F. Brown, University of Portsmouth *Table of Contents1: Introduction Part 1 Drug targets 2: Receptors and signal transduction 3: Enzymes as drug targets 4: Nucleic acids and protein synthesis as drug targets 5: Other drug targets Part 2 Origins of drug molecules 6: Sources of lead compounds 7: Drug synthesis 8: Optimisation of lead compounds 9: Computer-aided drug design 10: Combinatorial chemistry and high-throughput screening 11: Biotechnology and biopharmaceuticals Part 3 Biological aspects of drug development 12: Drug metabolism 13: Pharmacogenetics and pharmacogenomics 14: Toxicity testing Part 4 Preformulation studies 15: Solubility and drug development 16: Solid state characteristics 17: Drug stability Part 5 Clinical research 18: Clinical research and its regulation 19: Design and management of clinical trials

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisTable of ContentsUnit I: Basic Concepts and Principles in Pharmacology 1. Introduction to Respiratory Care Pharmacology 2. Principles of Drug Action 3. Administration of Aerosolized Agents 4. Calculating Drug Doses 5. The Central and Peripheral Nervous Systems Unit II: Drugs Used to Treat the Respiratory System 6. Adrenergic (Sympathomimetic) Bronchodilators 7. Anticholinergic (Parasympatholytic) Bronchodilators 8. Xanthines 9. Mucus-Controlling Drug Therapy 10. Surfactant Agents 11. Corticosteriods in Respiratory Care 12. Nonsteroidal Antiasthma Agents 13. Aerosolized Antiinfective Agents 14. Antimicrobial Agents 15. Cold and Cough Agents 16. Selected Agents of Pulmonary Value 17. Neonatal and Pediatric Aerosolized Drug Therapy Unit III: Critical Care, Cardiovascular, and Polysomnography Agents 18. Skeletal Muscle Relaxants (Neuromuscular Blocking Agents) 19. Diuretic Agents 20. Drugs Affecting the Central Nervous System 21. Vasopressors, Inotropes, and Antiarrythmic Agents 22. Drugs Affecting Circulation: Antihypertensives, Antianginals, Antithrombotics 23. Sleep and Sleep Pharmacology Appendix A: Answers to Self-Assessment Questions and Clinical Scenarios Appendix B: Units and Systems of Measurement Appendix C: Acceptable Mixtures of Most Commonly Prescribed Respiratory Care Drugs Glossary of Selected Terms Drug Index Abbreviations

Read more less

Book SynopsisTable of Contents1. Vector borne diseases Natural product Manangement : Current and Future perspectives 2. Evidence-based review of natural products for the management Onchocerciasis 3. Plant-derived compounds as potential treatment for arboviruses 4. Natural products in the management of Onchocerciasis 5. Combating the vectors and management of vector - borne diseases with essential oil nanoemulsions 6. Natural product for management of babesiosis 7. Antimicrobial Peptides, Nanocarrier systems, and Databases: Therapeutic Platform against Leishmaniasis 8. Marine Organisms as Natural Drug Leads in Combating Vector-Borne Diseases 9. Plant and Marine-Derived Antimalarial Agents 10. Natural products in the management of Schistosomiasis 11. An update on Antileishmanial Agents from Natural Resources 12. Plants with anti-dengue properties: A systematic review 13. Natural Products in Japanese Encephalitis 14. Algae natural products for potential vector borne disease management 15. Natural products in the management of Trypanosomiasis 16. Role of Ayurveda in vector born disease management 17. Medically important vector borne disease control through seaweeds against the virus disease Chikungunya 18. "Nano-biomaterials as novel modules in the delivery of Artemisinin and its derivatives for effective management of malaria" 19. Scientific and ethnopharmacological evidence of Carica papaya for the effective management of vector-borne disease 20. Nanoemulsion as a promising carrier of plant-derived repellents for mosquito-borne malaria control: Nanotechnology aspects 21. Insect repellent plants: A recent update 22. Natural Products Employed in the Management of Malaria

Read more less

Book SynopsisTable of Contents1. What is Pharmacology? 2. How Different Tissues Process Drug Response 3. Drug–Receptor Theory 4. Pharmacological Assay Formats: Binding 5. Drug Targets and Drug-Target Molecules 6. Agonists: The Measurement of Affinity and Efficacy in Functional Assays 7. Orthosteric Drug Antagonism 8. Allosteric Modulation 9. The Optimal Design of Pharmacological Experiments 10. Pharmacokinetics 11. Safety Pharmacology 12. The Drug Discovery Process 13. Selected Pharmacological Methods

Read more less

Book SynopsisMany new drugs on the market are chiral compounds, that is, they can exist in two non-superimposable mirror-image forms. Asymmetric catalysis encompasses a large variety of processes for obtaining such compounds. The performance of the catalyst in those processes largely depends on the ligand that makes up the catalyst. This book describes the most relevant ligand libraries for some key processes, including an overview of the state of art and the key mechanistic aspects that favor a high catalytic performance.Key Features: The book presents historical content from the time of discovery for each family of ligands. Provides a description of the synthetic route and the ligand library's application in various catalytic asymmetric reactions Suitable as supplementary reading for courses targeting the design, synthesis and application of chiral catalysts, asymmetric catalysis and sustainable production Edited by a distinguished scientist in the

Read more less

Book SynopsisAdvances in knowledge and technology have revolutionized the process of drug development, making it possible to design drugs for a given target or disease. Building on the foundation laid by the previous three editions, Smith and Williamsâ Introduction to the Principles of Drug Design and Action, Fourth Edition includes the latest information on topics such as gene therapy, computer-aided design, and molecular techniques including proteomics. Using real-world examples that illustrate the principles of drug design, the author explores the discovery of lead compounds and their manipulation in the production of non-toxic, metabolically stable drug candidates that will interact with target receptors in a predicted fashion.See whatâs new in the Fourth Edition: Fully updates and expands the contents Coverage of agonists and antagonists of neuro-transmitters Information on the design of stable peptide-like drugs The human genome and its impact on drug discovery and development Advances in therapy and pharmacokinetics Adopting a from-the-bench-to-the-marketplace approach, the book provides a thorough grounding in rational drug design. It emphasizes principles and elucidates a framework for basic drug design into which current and, more importantly, future drugs will fit.Trade Review“This book consists of 17 chapters on a variety of topics related to drug design and action. … This book is intended as a possible text for undergraduate chemistry students interested in medicinal chemistry, or for graduate students as a means to learn the basics of medicinal chemistry. … classical approaches are described for drug design with the inclusion of the more recent context of the human genome project … In summary, some medicinal chemists in academia or the pharmaceutical industry may find this book instructive for certain classes of biomolecules or classical approaches to drug design. It should probably be included in most comprehensive library collections of medicinal chemistry texts and monographs.” — Bruce L. Currie, Department of Pharmaceutical Sciences, Loma Linda University, California, in Journal of Medicinal Chemistry, , Vol. 50, No. 1, 2007 “The fourth edition of this book includes the latest information on topics such as gene therapy, computer-aided design, and molecular techniques including proteomics. … real-world examples that illustrate the principles of drug design … New features of this edition include: coverage of agonists and antagonists of neurotransmitters; the design of stable peptide-like drugs; the human genome and its impact on drug discovery and development; advances in therapy and pharmacokinetics.” — In Anticancer Research, Vol. 26, 2006 Promo CopyTable of ContentsProcesses of Drug Handling by the Body. The Design of Drug Delivery Systems. Fundamental Pharmacokinetics. Intermolecular Forces and Molecular Modeling. Drug Chirality and its Pharmacological Consequences. Quantitative Structure–Activity Relationships (QSAR) in Drug Design. Prodrugs. From Program Sanction to Clinical Trials: A Partial View of the Quest for Arimidex, A Potent, Selective Inhibitor of Aromatase. Design of Enzyme Inhibitors as Drugs. Peptide Drug Design. Combinatorial Chemistry: A Tool for Drug Discovery. Recombinant DNA Technology: Monoclonal Antibodies. The Human Genome and its Impact on Drug Discovery and Therapy. The Chemotherapy of Cancer. Neurotransmitters, Agonists, and Antagonists. Design of Antibacterial, Antifungal, and Antiviral Agents. Pharmaceutical Applications of Bioinorganic Chemistry. Index.

Read more less